KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Promising advances in treatments for the management of idiopathic pulmonary fibrosis.

Carmelo Sofia, Alessia Comes, Giacomo Sgalla, Luca Richeldi

Expert Opin Pharmacother 25(6) 717-725

PMID38832823
PMCID-
DOI10.1080/14656566.2024.2354460
发表日期2024-06-04
摘要

摘要

INTRODUCTION: Following the INPULSIS and ASCEND studies, leading to the first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents for a targeted effective and better tolerated therapy able to improve the natural history of the disease. AREAS COVERED: This review aims to analyze recent advances in pharmacological research of IPF, discussing the currently available treatments and the novel drugs under investigation in phase 3 trials, with particular emphasis on BI 1015550 and inhaled treprostinil. The literature search utilized Medline and Clinicaltrials.org databases. Critical aspects of clinical trial design in IPF are discussed in light of recently completed phase III studies. EXPERT OPINION: While randomized clinical trials in IPF are currently underway, future objectives should explore potential synergistic benefits when combining novel molecules with the existing therapies and identify more specific molecular targets. Moreover, refining the study design represent another crucial goal. The aim of the pharmacological research will be not only stabilizing but also potentially reversing the fibrotic changes in IPF.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。